RT Journal Article SR Electronic T1 Genome-Wide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.23.20076208 DO 10.1101/2020.04.23.20076208 A1 Chua, Katherina C. A1 Xiong, Chenling A1 Ho, Carol A1 Mushiroda, Taisei A1 Jiang, Chen A1 Mulkey, Flora A1 Lai, Dongbing A1 Schneider, Bryan P. A1 Rashkin, Sara R. A1 Witte, John S. A1 Friedman, Paula N. A1 Ratain, Mark J. A1 McLeod, Howard L. A1 Rugo, Hope S. A1 Shulman, Lawrence N. A1 Kubo, Michiaki A1 Owzar, Kouros A1 Kroetz, Deanna L. YR 2020 UL http://medrxiv.org/content/early/2020/06/19/2020.04.23.20076208.abstract AB Microtubule targeting agents (MTAs) are anticancer therapies commonly prescribed for breast cancer and other solid tumors. Sensory peripheral neuropathy (PN) is the major dose-limiting toxicity for MTAs and can limit clinical efficacy. The current pharmacogenomic study aimed to identify genetic variations that explain patient susceptibility and drive mechanisms underlying development of MTA-induced PN. A meta-analysis of genome-wide association studies (GWAS) from two clinical cohorts treated with MTAs (CALGB 40502 and CALGB 40101) was conducted using a Cox regression model with cumulative dose to first instance of grade 2 or higher PN. Summary statistics from a GWAS of European subjects (n = 469) in CALGB 40502 that estimated cause-specific risk of PN were meta-analyzed with those from a previously published GWAS of European ancestry (n = 855) from CALGB 40101 that estimated the risk of PN. Novel single nucleotide polymorphisms in an enhancer region downstream of sphingosine-1-phosphate receptor 1 (S1PR1 encoding S1PR1; e.g., rs74497159, βCALGB 40101 per allele log hazard ratio (95% CI) = 0.591 (0.254 - 0.928), βCALGB 40502 per allele log hazard ratio (95% CI) = 0.693 (0.334 - 1.053); PMETA = 3.62×10−7) were the most highly ranked associations based on P-values with risk of developing grade 2 and higher PN. In silico functional analysis identified multiple regulatory elements and potential enhancer activity for S1PR1 within this genomic region. Inhibition of S1PR1 function in iPSC-derived human sensory neurons shows partial protection against paclitaxel-induced neurite damage. These pharmacogenetic findings further support ongoing clinical evaluations to target S1PR1 as a therapeutic strategy for prevention and/or treatment of MTA-induced neuropathy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00785291 and NCT00041119Funding StatementResearch reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R01 CA192156 (D.L.K), U10 CA180821, U10 CA180882, and U24 CA196171 (Alliance for Clinical Trials in Oncology), UG1 CA233320 and UG1 CA233327 (NCTN). Research was also supported by a grant from the Breast Cancer Research Foundation and support from Give Breast Cancer the Boot through the Helen Diller Family Cooperative Cancer Center (D.L.K.). K.C.C. was supported in part by NIH grant T32 GM007175. K.O. was supported in part by NCI grant P01CA142538. Also supported in part by Abraxis, Bristol-Myers, and Celgene for CALGB 40502 (https://acknowledgments.alliancefound.org). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Pharmacogenetic analysis was approved by Institutional Review Boards at the National Cancer Institute and the University of California San Francisco.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenotype and phenotype data into NCBI dbGAP submission is in progress.